This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bio-Rad (BIO) Global Expansion Strong, FX Woe Dents Growth
by Zacks Equity Research
Bio-Rad (BIO) experiences double-digit currency-neutral core revenue growth in the Americas and Asia in Q4.
BD (BDX) Boosts Molecular Diagnostics Portfolio With New Tests
by Zacks Equity Research
Recent developments in the Molecular Diagnostics space have been aiding key MedTech players like BD (BDX) to boost their business.
Bio-Rad (BIO) Q4 Earnings Miss Estimates, Operating Margin Up
by Zacks Equity Research
Excluding COVID-related sales, Life Science revenues at Bio-Rad (BIO) increase 28.1%, primarily driven by Droplet Digital PCR, process chromatography, Western blotting and qPCR products.
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of -4.06% and 2.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Misses Q1 Earnings Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -27.27% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Sustained sales gains in terms of the Bio-Rads (BIO) process media, western blotting, Droplet Digital PCR and qPCR products are likely to drive Q4 revenues.
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.
Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges
by Zacks Equity Research
Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.
Bio-Rad Laboratories (BIO) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 0.39% and 1.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this time.
Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Owing to the impact of the Russia-Ukraine war situation, supply chain constraints, as well as the inflationary situation, we expect Bio-Rad's (BIO) Life Science arm to experience a year-over-year decline.
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Walgreens (WBA) is expected to have registered growth in Q4 in its U.S. retail pharmacy business, banking on demand for vaccinations and tests amid the ongoing series of contagious virus spread.
Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
BD's (BDX) Latest Monkeypox PCR Assay Commercially Available
by Zacks Equity Research
BD's (BDX) new molecular RUO PCR assay is expected to aid in better managing the ongoing global monkeypox outbreak.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.
Patterson Companies (PDCO) Q1 Earnings & Sales Miss Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter 2023 results were adversely impacted by unfavorable currency movements.
Cooper Companies (COO) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal third-quarter earnings reflect solid segmental performance.
Here's Why You Should Retain AngioDynamics (ANGO) Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) continues to benefit from strength in segments but forex remains a woe.
Catalent (CTLT) Stock Down Despite Q4 Beat: Will it Recover?
by Zacks Equity Research
Catalent's (CTLT) fiscal fourth-quarter earnings beat but the stock falls 7.4% following the earnings release on Aug 29. Here we discuss the factors that are set to guide its share price going forward.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
What's in Store for Patterson Companies (PDCO) in Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at the Animal Health segment.